ArticleArchives of medical science : AMS2026
Survival benefits of chemotherapy, radiotherapy, and chemoradiotherapy in patients with unresectable intrahepatic cholangiocarcinoma: a population-based study.
Article in Archives of medical science : AMS, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: This population-based study aimed to evaluate the survival benefits of radiotherapy, chemotherapy, chemoradiotherapy, and non-chemoradiotherapy in patients with unresectable intrahepatic cholangiocarcinoma (ICC). Material and methods: We used the Surveillance, Epidemiology, and End Results (SEER) database's SEER*stat software (version 8.3.5) to gather data of patients diagnosed with unresectable ICC from 2000 to 2018. Survival curves were plotted using the Kaplan-Meier method, comparing the overall survival (OS) and cancer-specific survival (CSS) among patients who underwent radiotherapy, chemotherapy, chemoradiotherapy, or no therapy at all. Univariate and multivariate Cox regression models were employed to analyze the prognostic factors affecting these unresectable ICC patients. Results: From 2000 to 2018, we identified 11,753 cases of unresectable ICC from the SEER database. Of these, 4,531 (38.5%) patients underwent chemotherapy alone, 482 (4.1%) patients underwent radiotherapy alone, and 996 (8.5%) patients received a combination of both. A total of 5,744 (48.9%) patients did not receive chemoradiotherapy. The median OS was 8 months (95% CI: 8--9 months) for patients receiving chemotherapy alone, 7 months (95% CI: 6-8 months) for radiotherapy alone, 12 months (95% CI: 11-13 months) for chemoradiotherapy, and 3 months (95% CI: 3-3 months) for those not receiving chemoradiotherapy. The CSS findings were consistent with the OS results. The Cox regression models indicated that patient age, sex, grade classification, tumor diameter, and treatment modality were independent prognostic factors for unresectable ICC patients ( Conclusions: Chemoradiotherapy can enhance the OS and CSS of patients with unresectable ICC, compared to the use of chemotherapy or radiotherapy alone.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.